Aethlon Medical Announces Avian Flu Treatment Application

Aethlon Medical, Inc., (OTCBB:AEMD), a pioneer in
developing therapeutic devices for infectious disease, announced today
that it is expanding the applications of its Hemopurifier(TM)
treatment technology to include the H5N1 strain of the Avian Flu
Virus. The rapid progression of H5N1 infection allows only a brief
treatment window with antiviral drugs. The Hemopurifier will target
the direct capture of H5N1 and modulation of the immune response as a
means to treat when drugs are ineffective or unavailable. In order to
advance the H5N1 treatment application, Aethlon will manufacture and
ship the treatment devices to established influenza researchers who
will seek to establish the benefits of the Hemopurifier as a treatment
against Avian Flu.
   The application of the Hemopurifier to treat Avian Flu is based on
evolving research that indicates a primary cause of death in H5N1
infection is the release of inflammatory cells and chemicals known as
a "Cytokine Storm." As a result of cytokine storm, the immune system
is hyper-activated to the extent that the normal immune response of
clearing viruses, toxins, and infected cells becomes overshadowed by
the destruction of healthy red blood cells. Antiviral drugs are not
able to shut off a cytokine storm once it has been triggered. Thus,
those individuals with robust immune systems are actually at greater
risk than the immune compromised individuals who are most susceptible
to regular seasonal flu strains. The hyper-activation of the immune
system as a result of cytokine storm also fueled the Spanish Flu
Pandemic of 1918. That pandemic is credited with killing between 20-50
million individuals in eighteen months.
   The Hemopurifier offers the potential to provide the dual benefit
of clearing H5N1 and modulating the overproduction of cytokines. The
Hemopurifier is based on hemofiltration principals already indicated
as a treatment for sepsis and shock caused by cytokine overproduction.
In addition, the Hemopurifier design provides a mechanism to separate
H5N1 from circulation so that it can be captured by immobilized
affinity agents that bind to glycoproteins on the surface of the
virus. Therefore, the Hemopurifier combines the potential to tame the
immune system without destroying natural defenses, with the ability to
reduce the body burden of infectious H5N1 virus.

   About Aethlon Medical

   Aethlon Medical is developing the first medical device to treat
infectious disease. The device, known as the Hemopurifier(TM), is a
broad-spectrum treatment countermeasure against drug and vaccine
resistant bioweapons, naturally evolving pandemic threats, and chronic
infectious disease targets such as Hepatitis-C (HCV) and the Human
Immunodeficiency Virus (HIV). More information on Aethlon Medical and
the Hemopurifier(TM) technology can be found at
www.aethlonmedical.com.

   Certain of the statements herein may be forward-looking and
involve risks and uncertainties. Such forward-looking statements
involve assumptions, known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or
achievements of Aethlon Medical, Inc. to be materially different from
any future results, performance, or achievements expressed or implied
by the forward-looking statements. Such potential risks and
uncertainties include, without limitation, the Company's ability to
raise capital when needed, the Company's ability to complete the
development of its planned products, the ability of the Company to
obtain FDA and other regulatory approvals permitting the sale of its
products, the Company's ability to manufacture its products and
provide its services, the impact of government regulations, patent
protection on the Company's proprietary technology, product liability
exposure, uncertainty of market acceptance, competition, technological
change, and other risk factors. In such instances, actual results
could differ materially as a result of a variety of factors, including
the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and
Exchange Commission filings.